Login to Your Account



Adventrx Acquires SynthRx, Revives Sickle Cell Drug P188

By Tom Wall


Tuesday, February 15, 2011
Adventrx Pharmaceuticals Inc. is hoping to revive a sickle cell anemia drug that all but disappeared after a disappointing Phase III trial in 1999.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription